RxDoctor Payments Data

Samyuktha Sreenivasan, MD

Internal Medicine · Goodyear, AZNPI 1548526171

Payments from drug & device makers

$267in general payments, 2019–2025

Across 8 payments — averaging $33.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$116
  • Lundbeck LLC$49
  • Abbott$47
  • Edwards Lifesciences$25
  • GSK$19
  • Medtronic$12

What the payments were for

  • Food & beverage$15156%
  • Education$11644%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk1$116
Lundbeck LLC1$49
Abbott3$47
Edwards Lifesciences1$25
GSK1$19
Medtronic1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$267 in reported general payments places this provider in the 55th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$414,042
Medicare patients
5,287
Services billed
28,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$174,559
FarxigaDapagliflozin Propanediol53$67,725
TrulicityDulaglutide47$60,163
EliquisApixaban33$46,620
JanuviaSitagliptin Phosphate19$28,097
JardianceEmpagliflozin15$26,181
TradjentaLinagliptin18$22,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,495
XareltoRivaroxaban23$14,342
Breo ElliptaFluticasone/Vilanterol14$10,945
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,174
SymbicortBudesonide/Formoterol Fumarate26$6,727
Famotidine61$5,865
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,664
Atorvastatin Calcium588$4,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$174,559104 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$19$34,61352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →